rineterkib

N/A

Report date: 2022/09/16 13:45:35
NME

Base Information

Drug Namerineterkib
Drug Alias NameLTT-462
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionExtracellular-signal-regulated kinase1 inhibitorsExtracellular-signal-regulated kinase 2 inhibitors
TargetsExtracellular-signal-regulated kinase1Extracellular-signal-regulated kinase 2
Therapy Area/IndicationsSolid tumoursPrimary MyelofibrosisCarcinoma, Non-Small-Cell Lung +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[21] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Ag
Inactive CompaniesChina Novartis Institutes For Biomedical Research Co Ltd
Active IndicationsPrimary MyelofibrosisMelanoma
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A